In recent years, going overseas has long become an important way
for many domestic pharmaceutical companies to develop new business growth points.
With the continuous improvement of the innovation level of domestic pharmaceutical companies and the continuous improvement of the recognition of domestic drugs in overseas markets, more and more Chinese pharmaceutical companies are accelerating the promotion of domestic drugs overseas
while entering the international market.
Recently, it has been reported that the Kenyan Pharmaceutical Industry and Poisons Authority (PPB) approved the marketing of two vaccine products of Sinopharm China Biotech on December 13
, local time.
The two vaccine products are the quadrivalent influenza virus split vaccine developed and produced by Wuhan Institute of Biological Products, a subsidiary of China Biotechnology, and the live attenuated varicella vaccine
developed and produced by Changchun Qijian Biological Products Co.
, Ltd.
On December 5, Sinovac and partner PT Etana Biotechnologies Indonesia jointly announced that SINOVAC Sinovac hepatitis A inactivated vaccine Childreflex ® was officially launched
in Indonesia.
It is worth mentioning that Child-Rich ® was approved
by the Indonesian Food and Drug Administration in February this year.
In November, Sinovac's inactivated enterovirus 71 (EV71) vaccine was also approved
in Indonesia.
On December 2, Hansen Pharmaceutical announced that the European Medicines Agency (EMA) has officially accepted the third representative skin growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ametinib mesylate tablets submitted by the company's partner EQRx, Inc.
(EQRx) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR-sensitive mutations, and for the treatment of EGFR Marketing Authorization Application (MAA)
for adult patients with locally advanced or metastatic NSCLC positive for T790M mutation.
It is understood that this is the second marketing authorization application
for ametinib outside China after the UK MHRA in June 2022.
On November 24, Junshi Biologics announced that it has recently submitted a marketing authorization application
for the anti-PD-1 monoclonal antibody drug teripulimab to the UK Medicines and Healthcare Products Agency (MHRA).
The indications declared this time are: 1) teripulimab combined with cisplatin and gemcitabine for first-line treatment in patients with locally recurrent or metastatic nasopharyngeal carcinoma (NPC); 2) Teripulimab in combination with paclitaxel and cisplatin for first-line treatment
in patients with unresectable locally advanced/recurrent or metastatic esophageal squamous cell carcinoma (ESCC).
Previously, Junshi Biologics had submitted marketing authorization applications
for these two indications to the European Medicines Agency (EMA).
On September 26, Frontier Biotech mentioned at the performance statement meeting that Ekonin has obtained the marketing registration authorization
of Malaysian drugs.
The company said that it will continue to actively promote the commercialization process of Ekonin overseas in close connection with the business plan it has formulated, with a view to realizing the overseas business income
of Ekonin.
In fact, up to now, Ekonin has obtained drug marketing registration authorization in Ecuador, Cambodia and Malaysia, in addition to submitting drug registration applications in 7 countries, and 5 countries have carried out drug registration
.
.
.
.
.
.
.
More and more domestic drugs are listed overseas, which fully shows that the innovation and quality of domestic drugs are being recognized by more and more overseas markets
.
The industry expects that in the future, with the growth of the number of innovative drug INDs in China, the increase in the number of clinical trials, and the improvement of the quality and strength of domestic innovative drugs, domestic pharmaceutical companies will usher in more new market growth points
overseas.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
